What Is a JAK Inhibitor? How They Work, What They Treat, and the Risks to Know

JAK inhibitors are a class of medicines, mostly pills, that calm an overactive immune system. In just over a decade they have gone from a single arthritis drug to treatments for eczema, alopecia areata, vitiligo, ulcerative colitis, psoriatic arthritis and more. They can work remarkably well, sometimes where nothing else has — and they carry serious warnings that are worth understanding. This guide explains both.

What “JAK” means

JAK stands for Janus kinase, a family of four enzymes inside cells: JAK1, JAK2, JAK3 and TYK2. They act as relay switches. When immune messenger proteins called cytokines dock on the outside of a cell, JAKs pass the signal inward, switching on genes that drive inflammation. In autoimmune and inflammatory diseases, that signaling is stuck in overdrive.

How JAK inhibitors work

A JAK inhibitor blocks one or more of those enzymes, interrupting many inflammatory signals at once. That is the key difference from biologic drugs such as Humira or Dupixent, which are injected antibodies that each block one specific cytokine or receptor. Because JAK inhibitors are small molecules, most can be taken as tablets, and they tend to act quickly — itch in eczema, for example, can improve within days.

What they treat

Approved uses now span several specialties:

• Joints: rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis.
• Skin: atopic dermatitis (eczema), vitiligo, chronic hand eczema, and plaque psoriasis (via a related TYK2 inhibitor).
• Hair: severe alopecia areata.
• Gut: ulcerative colitis and Crohn’s disease.
• Blood: myelofibrosis and polycythemia vera, bone marrow disorders driven by JAK2, and graft-versus-host disease.

The main JAK inhibitors

Xeljanz (tofacitinib) was the first for an inflammatory disease, approved in 2012. Olumiant (baricitinib) and Rinvoq (upadacitinib) followed, with Rinvoq gathering the widest range of approvals across joints, skin and gut. Cibinqo (abrocitinib) is used for eczema. Litfulo (ritlecitinib) and Leqselvi (deuruxolitinib) were approved specifically for alopecia areata. Jakafi (ruxolitinib) treats blood disorders, and the same molecule in a cream, Opzelura, treats eczema and vitiligo. Sotyktu (deucravacitinib) selectively blocks TYK2 for psoriasis.

JAK inhibitors and hair loss

The most searched use is alopecia areata, an autoimmune condition in which the immune system attacks hair follicles. Until 2022 there was no approved treatment. Three JAK inhibitors are now approved for severe cases — Olumiant, Litfulo (from age 12) and Leqselvi — and Olumiant’s approval was extended to adolescents in 2026. In trials, roughly a third or more of patients regrew most of their scalp hair within about six months to a year. Two caveats matter: they do not work for everyone, and hair loss often returns if the drug is stopped. They are not treatments for common male- or female-pattern baldness.

Creams versus pills

Topical JAK inhibitors, such as ruxolitinib cream for eczema and vitiligo, deliver the drug to the skin with much less reaching the bloodstream. They still carry the class warning on their labels, but the amount absorbed is far lower than with tablets when used as directed on limited areas. For localized skin disease, a cream can offer a JAK inhibitor’s benefits with less systemic exposure.

The boxed warning

Oral JAK inhibitors for inflammatory diseases carry the FDA’s strongest caution, a boxed warning, for serious infections, death, cancer, major cardiovascular events (heart attack and stroke) and blood clots. It stems largely from a large safety study of tofacitinib in people with rheumatoid arthritis who were 50 or older with at least one heart-disease risk factor; compared with TNF-blocking biologics, tofacitinib was linked to more of these events. In 2021 the FDA extended the warning across the class and advised that these drugs generally be used after TNF blockers have failed in arthritis.

How much of that risk applies to a healthy 25-year-old with eczema or alopecia is debated; the risk appears concentrated in older people, smokers, and those with existing heart or clotting risks. But the warning is on the label for everyone, and it should be part of the conversation.

Other side effects and monitoring

More common effects include upper respiratory infections, acne, headache, nausea, raised cholesterol and shingles. Before starting, doctors usually test for tuberculosis and hepatitis, check blood counts, liver function and lipids, and recommend bringing vaccines up to date — including the shingles vaccine — since live vaccines should be avoided during treatment. Blood tests are repeated periodically. JAK inhibitors are generally not used during pregnancy.

Questions to ask your doctor

• Have I tried the alternatives, and why is a JAK inhibitor the right next step?
• Given my age, smoking history and heart or clot risk, how does the boxed warning apply to me?
• What tests and vaccines do I need before starting, and how often will I be monitored?
• How long before we know if it is working, and what happens if I stop?

For many people, JAK inhibitors are life-changing; for others, a different drug is the safer choice. The decision depends on the condition, its severity, and the individual’s risks. This explainer is general information, not medical advice.